Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Chief Strategy Officer and CFO | July 28, 2026 | July 31, 2026 |
| Rain Oncology Inc.RAIN · Entity 94695 | Director | January 26, 2024 | January 26, 2024 |
| Sierra Oncology, Inc.SRRA · Entity 125698 | Director | June 11, 2019 | June 12, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROTHENA CORP PUBLIC LTD CO
Report date July 28, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative | Direct | 40,205 |
Ending reported balance
After 2026-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Exercise / conversion · Acquired 57,000 · Balance 97,205 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Row 2 · 2026-07-28 · Disposition to issuer · Disposed 57,000 · Balance 40,205 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-28 · Exercise / conversion · Disposed 57,000 · Balance 0 F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 95,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 95,000 RSUs reported in Table I (38,000 RSUs) are subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.
F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 95,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.
F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 95,000 RSUs reported in Table I (38,000 RSUs) are subject to vesting.
Rain Oncology Inc.
Report date January 26, 2024 · Filed January 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-26 · Disposition to issuer · Disposed 13,890 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-26 · Disposition to issuer · Disposed 42,596 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-26 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-26 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.
Sierra Oncology, Inc.
Report date June 11, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2029-06-11 | Direct | 30,000 |
Reported balance
After 2019-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 31, 2026 00:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionRestricted Stock Units · Derivative | 57,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-003413 · form4.xml · derivative · entry 3 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 57,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 95,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3 · derivative.exercise_date: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 95,000 RSUs reported in Table I (38,000 RSUs) are subject to vesting. F3 · derivative.expiration_date: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 95,000 RSUs reported in Table I (38,000 RSUs) are subject to vesting. Read SEC document |
| July 28, 2026 Filed Jul 31, 2026 00:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerOrdinary Shares, par value $0.01 per share | 57,000 | $8.56 | $487,920.00 |
DisclosureSEC source: 0000905148-26-003413 · form4.xml · nonDerivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,205 Read SEC document |
| July 28, 2026 Filed Jul 31, 2026 00:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 57,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-26-003413 · form4.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,205 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:50 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 230,000 | $0.00 Strike: $9.36 | $0.00 |
DisclosureSEC source: 0000905148-26-001178 · form4.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 Underlying: Ordinary Shares · 230,000 shares Expires 2036-03-03 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 3, 2027, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| July 28, 2025 Filed Jul 30, 2025 21:51 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantOrdinary Shares, par value $0.01 per share | 95,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002658 · form4.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,205 Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 107,500 | $0.00 Strike: $14.95 | $0.00 |
DisclosureSEC source: 0000905148-25-000886 · form4.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,500 Underlying: Ordinary Shares · 107,500 shares Expires 2035-03-05 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 5, 2026, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 27, 2024 Filed Mar 1, 2024 02:07 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $30.30 | $0.00 |
DisclosureSEC source: 0000905148-24-000838 · form4.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Ordinary Shares · 85,000 shares Expires 2034-02-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2025, and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:47 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001999371-24-000972 · ownership.xml · derivative · entry 4 Nguyen Tran · CIK 0001457013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:47 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,000 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001999371-24-000972 · ownership.xml · derivative · entry 3 Nguyen Tran · CIK 0001457013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:47 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 42,596 | Not disclosed Strike: $3.13 | Not disclosed |
DisclosureSEC source: 0001999371-24-000972 · ownership.xml · derivative · entry 2 Nguyen Tran · CIK 0001457013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,596 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:47 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,890 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0001999371-24-000972 · ownership.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,890 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F1 · derivative.expiration_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 21:11 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001104659-23-090701 · tm2323614-6_4seq1.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-08-09 F1 · derivative.exercise_date: This option represents a right to purchase a total of 35,000 shares of the Issuer's common stock, which will vest in full on the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $22.85 | $0.00 |
DisclosureSEC source: 0001140361-23-025342 · form4.xml · derivative · entry 9 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 50,000 shares Expires 2025-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: All shares subject to the option have fully vested. F7 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 806,837 shares at exercise prices ranging from $12.15 to $52.97, of which 638,253 are currently exercisable, and 168,584 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to the Court Order. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $29.81 | $0.00 |
DisclosureSEC source: 0001140361-23-025342 · form4.xml · derivative · entry 8 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 45,000 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: All shares subject to the option have fully vested. F7 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 806,837 shares at exercise prices ranging from $12.15 to $52.97, of which 638,253 are currently exercisable, and 168,584 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to the Court Order. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 100 | $76.04 | $7,604.00 |
DisclosureSEC source: 0001140361-23-025342 · form4.xml · nonDerivative · entry 7 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 10, 2023 in connection with a court stipulation and order regarding the separation of assets ("Court Order") in accordance with a divorce settlement agreement. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 9,215 | $75.44 | $695,206.32 |
DisclosureSEC source: 0001140361-23-025342 · form4.xml · nonDerivative · entry 6 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,300 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 10, 2023 in connection with a court stipulation and order regarding the separation of assets ("Court Order") in accordance with a divorce settlement agreement. F5 · price: The transaction was executed in multiple trades in prices ranging from $75.04 to $76.025, inclusive. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 37,044 | $74.55 | $2,761,474.62 |
DisclosureSEC source: 0001140361-23-025342 · form4.xml · nonDerivative · entry 5 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,515 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 10, 2023 in connection with a court stipulation and order regarding the separation of assets ("Court Order") in accordance with a divorce settlement agreement. F4 · price: The transaction was executed in multiple trades in prices ranging from $74.03 to $75.02, inclusive. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 34,640 | $73.54 | $2,547,311.29 |
DisclosureSEC source: 0001140361-23-025342 · form4.xml · nonDerivative · entry 4 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,559 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 10, 2023 in connection with a court stipulation and order regarding the separation of assets ("Court Order") in accordance with a divorce settlement agreement. F3 · price: The transaction was executed in multiple trades in prices ranging from $73.03 to $74.025, inclusive. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 14,001 | $72.66 | $1,017,325.26 |
DisclosureSEC source: 0001140361-23-025342 · form4.xml · nonDerivative · entry 3 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,199 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 10, 2023 in connection with a court stipulation and order regarding the separation of assets ("Court Order") in accordance with a divorce settlement agreement. F2 · price: The transaction was executed in multiple trades in prices ranging from $72.03 to $73.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the ranges set forth in footnotes 2 through 5 of this Form 4. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 50,000 | $22.85 | $1,142,500.00 |
DisclosureSEC source: 0001140361-23-025342 · form4.xml · nonDerivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2023 Filed May 18, 2023 01:53 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 45,000 | $29.81 | $1,341,450.00 |
DisclosureSEC source: 0001140361-23-025342 · form4.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001567619-23-005291 · doc1.xml · derivative · entry 4 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 10,000 shares Expires 2023-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on April 1, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately one month and be forfeited to the extent it is not exercised on or prior to March 31, 2023. F5 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 901,837 shares at exercise prices ranging from $6.73 to $52.97, of which 721,837 are currently exercisable, and 180,000 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to the Court Order. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 5,198 | $48.68 | $253,028.76 |
DisclosureSEC source: 0001567619-23-005291 · doc1.xml · nonDerivative · entry 3 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and order regarding the separation of assets ("Court Order") in accordance with a divorce settlement agreement. F3 · price: The transaction was executed in multiple trades in prices ranging from $48.43 to $49.03, inclusive. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,802 | $48.16 | $231,285.45 |
DisclosureSEC source: 0001567619-23-005291 · doc1.xml · nonDerivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,398 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and order regarding the separation of assets ("Court Order") in accordance with a divorce settlement agreement. F2 · price: The transaction was executed in multiple trades in prices ranging from $47.43 to $48.405, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 10,000 | $6.73 | $67,300.00 |
DisclosureSEC source: 0001567619-23-005291 · doc1.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2023 Filed Mar 4, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 48,000 | $0.00 Strike: $52.97 | $0.00 |
DisclosureSEC source: 0001140361-23-010183 · form4.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Ordinary Shares · 48,000 shares Expires 2033-03-02 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 2, 2024 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. F2 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 911,837 shares at exercise prices ranging from $6.73 to $52.97, of which 731,837 are currently exercisable, and 180,000 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to an order regarding the separation of assets in accordance with a divorce settlement agreement. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001567619-23-003363 · doc1.xml · derivative · entry 4 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2023-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on April 1, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately two months and be forfeited to the extent it is not exercised on or prior to March 31, 2023. F5 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 863,837 shares at exercise prices ranging from $6.73 to $32.45, of which 704,669 are currently exercisable, and 159,168 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to the Court Order. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 664 | $53.87 | $35,770.68 |
DisclosureSEC source: 0001567619-23-003363 · doc1.xml · nonDerivative · entry 3 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and order regarding the separation of assets ("Court Order") in accordance with a divorce settlement agreement. F3 · price: The transaction was executed in multiple trades in prices ranging from $53.87 to $53.88, inclusive. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 9,336 | $53.30 | $497,626.54 |
DisclosureSEC source: 0001567619-23-003363 · doc1.xml · nonDerivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,864 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and order regarding the separation of assets ("Court Order") in accordance with a divorce settlement agreement. F2 · price: The transaction was executed in multiple trades in prices ranging from $52.835 to $53.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 10,000 | $6.73 | $67,300.00 |
DisclosureSEC source: 0001567619-23-003363 · doc1.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2023 Filed Jan 21, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001567619-23-001097 · doc1.xml · derivative · entry 5 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 10,000 shares Expires 2023-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on April 1, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately two months and be forfeited to the extent it is not exercised on or prior to March 31, 2023. F6 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 873,837 shares at exercise prices ranging from $6.73 to $32.45, of which 708,753 are currently exercisable, and 165,084 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to the Court Order. Read SEC document |
| January 18, 2023 Filed Jan 21, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 638 | $56.97 | $36,347.43 |
DisclosureSEC source: 0001567619-23-001097 · doc1.xml · nonDerivative · entry 4 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F4 · price: The transaction was executed in multiple trades in prices ranging from $56.815 to $57.355, inclusive. Read SEC document |
| January 18, 2023 Filed Jan 21, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,085 | $56.32 | $117,435.96 |
DisclosureSEC source: 0001567619-23-001097 · doc1.xml · nonDerivative · entry 3 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,838 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F3 · price: The transaction was executed in multiple trades in prices ranging from $55.78 to $56.755, inclusive. Read SEC document |
| January 18, 2023 Filed Jan 21, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 7,277 | $55.18 | $401,523.03 |
DisclosureSEC source: 0001567619-23-001097 · doc1.xml · nonDerivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,923 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F2 · price: The transaction was executed in multiple trades in prices ranging from $54.77 to $55.755, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 4 of this Form 4. Read SEC document |
| January 18, 2023 Filed Jan 21, 2023 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 10,000 | $6.73 | $67,300.00 |
DisclosureSEC source: 0001567619-23-001097 · doc1.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2022 Filed Dec 24, 2022 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001567619-22-022010 · doc1.xml · derivative · entry 4 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 10,000 shares Expires 2023-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on April 1, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately three months and be forfeited to the extent it is not exercised on or prior to March 31, 2023. F5 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 883,837 shares at exercise prices ranging from $6.73 to $32.45, of which 712,836 are currently exercisable, and 171,001 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to the Court Order. Read SEC document |
| December 21, 2022 Filed Dec 24, 2022 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 6,845 | $59.21 | $405,264.39 |
DisclosureSEC source: 0001567619-22-022010 · doc1.xml · nonDerivative · entry 3 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F3 · price: The transaction was executed in multiple trades in prices ranging from $58.87 to $59.86, inclusive. Read SEC document |
| December 21, 2022 Filed Dec 24, 2022 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,155 | $58.46 | $184,425.84 |
DisclosureSEC source: 0001567619-22-022010 · doc1.xml · nonDerivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,045 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F2 · price: The transaction was executed in multiple trades in prices ranging from $57.855 to $58.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 3 of this Form 4. Read SEC document |
| December 21, 2022 Filed Dec 24, 2022 02:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 10,000 | $6.73 | $67,300.00 |
DisclosureSEC source: 0001567619-22-022010 · doc1.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2022 Filed Nov 26, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001140361-22-043172 · form4.xml · derivative · entry 5 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Ordinary Shares · 10,000 shares Expires 2023-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on April 1, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately four months and be forfeited to the extent it is not exercised on or prior to March 31, 2023. F6 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 893,837 shares at exercise prices ranging from $6.73 to $32.45, of which 720,857 are currently exercisable, and 172,980 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to the Court Order. Read SEC document |
| November 23, 2022 Filed Nov 26, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,469 | $62.28 | $91,487.56 |
DisclosureSEC source: 0001140361-22-043172 · form4.xml · nonDerivative · entry 4 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F4 · price: The transaction was executed in multiple trades in prices ranging from $61.91 to $62.685, inclusive. Read SEC document |
| November 23, 2022 Filed Nov 26, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,984 | $61.28 | $244,125.18 |
DisclosureSEC source: 0001140361-22-043172 · form4.xml · nonDerivative · entry 3 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,669 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F3 · price: The transaction was executed in multiple trades in prices ranging from $60.90 to $61.885, inclusive. Read SEC document |
| November 23, 2022 Filed Nov 26, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,547 | $60.53 | $275,240.82 |
DisclosureSEC source: 0001140361-22-043172 · form4.xml · nonDerivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,653 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F2 · price: The transaction was executed in multiple trades in prices ranging from $59.885 to $60.88, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 4 of this Form 4. Read SEC document |
| November 23, 2022 Filed Nov 26, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 10,000 | $6.73 | $67,300.00 |
DisclosureSEC source: 0001140361-22-043172 · form4.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2022 Filed Oct 22, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001567619-22-018716 · doc1.xml · derivative · entry 6 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 10,000 shares Expires 2023-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on April 1, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately five months and be forfeited to the extent it is not exercised on or prior to March 31, 2023. F7 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 903,837 shares at exercise prices ranging from $6.73 to $32.45, of which 721,003 are currently exercisable, and 182,834 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to the Court Order. Read SEC document |
| October 19, 2022 Filed Oct 22, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 171 | $58.17 | $9,947.86 |
DisclosureSEC source: 0001567619-22-018716 · doc1.xml · nonDerivative · entry 5 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F5 · price: The transaction was executed in multiple trades in prices ranging from $58.05 to $58.20, inclusive. Read SEC document |
| October 19, 2022 Filed Oct 22, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,541 | $57.30 | $260,212.47 |
DisclosureSEC source: 0001567619-22-018716 · doc1.xml · nonDerivative · entry 4 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,371 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F4 · price: The transaction was executed in multiple trades in prices ranging from $56.84 to $57.72, inclusive. Read SEC document |
| October 19, 2022 Filed Oct 22, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,520 | $56.30 | $141,885.32 |
DisclosureSEC source: 0001567619-22-018716 · doc1.xml · nonDerivative · entry 3 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,912 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F3 · price: The transaction was executed in multiple trades in prices ranging from $55.805 to $56.77, inclusive. Read SEC document |
| October 19, 2022 Filed Oct 22, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,768 | $55.04 | $152,339.65 |
DisclosureSEC source: 0001567619-22-018716 · doc1.xml · nonDerivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,432 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F2 · price: The transaction was executed in multiple trades in prices ranging from $54.78 to $55.765, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnotes 2 through 5 of this Form 4. Read SEC document |
| October 19, 2022 Filed Oct 22, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 10,000 | $6.73 | $67,300.00 |
DisclosureSEC source: 0001567619-22-018716 · doc1.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.